Treatment guidelines are continuously evolving in chronic viral hepatitis, taking into consideration our greater understanding of natural history and therapeutic efficacy and safety. Key in the decision making process is an assessment of liver injury. Traditionally, liver biopsy has provided this information; however, this is an invasive procedure and not completely reliable. Liver transient elastography (Fibroscan®) is exciting new technology that allows estimation of hepatic fibrosis through measurement of liver stiffness. It is acceptably accurate, safe, cheap, quick and widely applicable, and can reduce
the need for liver biopsy in chronic hepatitis. In chronic hepatitis C, it can identify those most likely to benefit from treatment, as well as those with cirrhosis who require more specific care. In chronic hepatitis B, it could screen groups previously excluded from treatment (normal alanine aminotransferase and low DNA) to identify the subgroup that would benefit from therapy. It cannot replace biopsy in all settings, but it will narrow the group who do require biopsy, and provide information on liver damage in patients for whom biopsy would probably not have been considered.
Vignette 1
A 51-year-old man with genotype 1 chronic hepatitis C infection requested treatment. There was no clinical, biochemical or radiological evidence of cirrhosis. He wished to avoid liver biopsy if at all possible, and is not required to undergo biopsy prior to treatment. Cirrhosis is not recognized, but is present. After treatment, he achieved a sustained virological response (SVR) and was discharged from the clinic. Two years later he presented with an advanced hepatocellular carcinoma (HCC). If his cirrhosis had been recognized, HCC surveillance could have been initiated, possibly resulting in an earlier detection and better opportunities for therapy.
Vignette 2
A 60-year-old hepatitis B surface antigen-positive, hepatitis B e antigen (HBeAg)-negative Chinese woman with normal liver enzymes (alanine aminotransferase [ALT] 36 IU/l) and a low HBV DNA (2,000 IU/ml) requests treatment. On the basis of her age, guidelines suggest she should consider a liver biopsy to exclude significant damage, but the patient is unwilling because her liver tests are normal and her relative had a serious complication from a biopsy. How should she be managed? Is a biopsy always necessary?
Liver biopsy in viral hepatitis
Liver biopsy has long had a central role in the management of chronic viral hepatitis. The presence of hepatic fibrosis is an important factor in predicting prognosis and guiding therapeutic decisions in chronic viral hepatitis. Demonstrated minimal hepatic damage might suggest a more benign disease course and reduce the impetus to treat the virus. Significant fibrosis increases the urgency for treatment. When cirrhosis is identified, screening for HCC and oesophageal varices becomes important. In the setting of viral hepatitis, the role of a liver biopsy is primarily for staging the degree of injury, not to achieve a diagnosis. The pattern and degree of fibrosis, with or without architectural distortion is described by the histopathologist. Characterization of the amount and pattern of inflammation ('activity') can be discerned. This information can be reported by well validated international scoring systems for hepatic injury (inflammation and fibrosis) in the context of viral hepatitis (Metavir, Schueur and Ishak) [1] . With costly and potentially toxic treatments for viral hepatitis, in some countries the documentation of significant liver injury was mandatory prior to the commencement of therapy. However, for a number of reasons, this has been changing. Although liver biopsy is the gold standard method used to assess hepatic fibrosis, its limitations need to be kept in mind. Differences in scoring between pathologists on the same biopsy (interobserver variation) or by the same pathologists on different days (intraobserver variation) has been described in up to 40% of cases [2, 3] . Sampling error might also be substantial. In a recent study, when two biopsies were taken simultaneously from different lobes of the same liver, the fibrosis score differed by one stage in 31% of cases, and more than one in 2.4% [4] . In cases of cirrhosis, this was only seen in one of the paired biopsies in 15% of cases. Some of this variance might result from the fact that the scoring systems for fibrosis are generally descriptive, rather than quantitative. The pathological processes themselves could affect the liver in a patchy distribution, with no defined solution for interpreting a biopsy with variance within the specimen. Biopsy size is also important, with accuracy in determining the stage of liver fibrosis as low as 65% when the biopsy length was 15 mm, but improving to 75% for a 25 mm biopsy [5] . It is generally considered that >5 portal tracts are needed for an accurate assessment [6, 7] , yet with this criteria, up to 50% of biopsies are inadequate for the accurate assessment of fibrosis [5, 7, 8] . It is considered by some that liver biopsy is instead a 'bronze standard' [9] . Procedure-related pain is common [10] , there is a small but significant major complication rate, and even death can occur [10] [11] [12] . Biopsy is also a relatively costly procedure [13] . Understandably, some patients might also be reluctant to proceed with a biopsy if they perceive that it might delay or prevent access to antiviral therapy. In view of the safety concerns and patient reluctance, liver biopsy is not a tool that can be used easily in the same patient to monitor progression of the liver disease or the response to treatment.
Non-invasive markers of liver fibrosis: general principles
In view of the limitations of liver biopsy, there has been much interest in the development of methods to measure liver fibrosis in chronic viral hepatitis without a biopsy -so called 'non-invasive markers'. Such markers include imaging techniques, breath tests, combinations of routine blood tests and specialized serum markers of fibrogenesis or extracellular matrix turnover. Most non-invasive markers, for example the aspartate aminotransferase to platelet ratio index (APRI) [14] , provides a number that is then interpreted using a high and low cutoff. A score above the high cutoff implies a high likelihood of advanced fibrosis and a score below the low cutoff implies high likelihood of minimal fibrosis. A score between the two cutoffs is an indeterminate result. Accuracy and degree of validation in predicting various degrees of hepatic fibrosis is variable. Some commercial operations propose conversion of non-invasive marker results into histological stages using a grid. The implication is that there is a consistent direct correlation of the serum marker score to fibrosis score (for example, the result of 0.5 equates to Metavir F2 [15] ); however, this probably oversimplifies the relationship between the serum marker and the fibrosis score without acknowledging limitations of the tests [16] . Nevertheless, their great advantage over liver biopsy is that they can usually be performed quickly, repeatedly, cheaply and safely.
The assessment of the accuracy of non-invasive markers is done by comparison with the results of liver biopsy. In view of the limitations of biopsy, particularly the intraobserver variance and sampling variance, perfect correlations can never be achieved. Whilst noninvasive markers of liver disease have their advantages and proponents, there are some general limitations in their development, use and interpretation.
Although liver biopsy is an imperfect standard, all non-biopsy markers of fibrosis are compared to it to establish the accuracy of the surrogate. Without a true gold standard this process is inherently flawed. In a recent calculation where biopsy sensitivity and specificity were assumed to be 90%, even a perfect non-biopsy marker could not achieve an area under the receiver operating characteristic curve (AUROC) of >0.9 [17] . However, until large long-term studies with clinical end points are undertaken to show the merit of a particular marker, the use of biopsy as the comparator will continue.
Biopsy scoring systems for liver fibrosis (for example, Metavir, Schueur, Ishak and histological activity index) give a number to a pattern of fibrosis (Table 1) , whereas non-invasive markers generate numbers to represent liver parameters other than fibrosis pattern (for example, liver function, liver stiffness, fibrosis formation or fibrosis quantity). It should also be remembered that the numerical fibrosis stage of a liver biopsy, despite the implication, does not reflect a linear increase in the quantity of fibrosis [1, 18] (Figure 1 ). For example, in the Scheuer system, the fibrosis score moves from F0 to F1 when the fibrosis within the portal tract moves above what is accepted as normal [19] . Likewise, progression from Scheuer fibrosis stage 3 to 4 occurs when the appearance progressed from 'architectural distortion but no cirrhosis' to 'probable or definite cirrhosis'. The bridging fibrosis quantity might be the same for F3 and F4. Even F2 can have a significant degree of bridging fibrosis, but remains F2 so long as there is no architectural disturbance, at which point it would become F3. These factors, in part, explain the difficulty with reproducibility of reporting liver biopsies, and limit the capacity for exact concordance between non-invasive markers and liver biopsy. This is particularly true in milder stages of fibrosis, where the quantity of fibrosis might be similar between stages, resulting in the potential for overlap in elastography scores.
Some non-invasive serum markers depend on a combination of routine laboratory tests and markers of fibrogenesis, which are often not routinely available. When collated into a patented algorithm (for example, FibroTest ® [FT]), they provide an indirect measure of fibrosis. The accuracy of the test can deteriorate when an individual component of the score is affected by an incidental process. For example, Gilbert's syndrome or haemolysis might affect the bilirubin, or acute inflammation could increase the components of α2-macroglobulin or haptoglobulin, which will affect the test result. The confounders limit their broader applicability in all but experienced centres [20] . Some non-invasive tests are available only in selected centres. Some might be more expensive than liver biopsy itself. In addition, the vast majority of published data validating these non-invasive markers has been on HCV, with relatively less published work on HBV and other liver conditions, although this is changing. Finally, when comparing two noninvasive markers, discordance of results for the one patient can only be resolved be prejudicing one test to be superior, or by proceeding to biopsy, which itself is not completely accurate.
Transient elastography: the practicalities
Transient elastography (TE), using Fibroscan ® (Echosens, Paris, France), is exciting new technology that assesses liver fibrosis by measuring liver stiffness. The patient reclines on an examination bed with the skin over the liver exposed. A probe is applied perpendicular to the skin and aimed between the ribs into the right lobe of the liver (similar position to a percutaneous biopsy). On depression of a button the probe produces a barely palpable low frequency mechanical shear wave that travels through the skin, subcutaneous tissues and then the liver. Once the shear wave is generated the probe immediately emits pulse echo ultrasounds that catch up to the shear wave and are reflected back to the probe. This enables the velocity of the shear wave to be measured. Once the shear wave velocity is known, it is multiplied by a mass density constant to produce the value for liver stiffness, measured in kPa. Increased liver stiffness correlates with increased liver fibrosis. As not all shear waves are suitable for analysis (for example, if transmitted through ribs or large vascular bundles), the machine will discard any such recordings. Once 10 acceptable measurements are performed, the median liver stiffness value is calculated and expressed with an interquartile range (ideally <30% of the median) and success rate (ideally >60% of all attempts).
This technique has a number of advantages. It takes approximately 5 min to perform and is painless. No fasting, sedation or analgesia is required; thus, it is well suited to outpatient clinics as part of a standard appointment. This technique samples a cylinder of liver tissue 1 cm wide and 4 cm long beginning 2.5 cm below the skin. This is at least 100× more tissue than sampled by a single liver biopsy. The result is operator independent and high success rates can be achieved after minimal training [21] . Reproduced from [1] with permission from BMJ Publishing Group Ltd. The collagen proportionate area (CPA) is the percentage of the area of a biopsy specimen that is occupied by collagen (that is, fibrosis). Note that the relationship is not linear.
Transient elastography: accuracy
The number of publications comparing TE to liver biopsy have increased dramatically in the past 3 years, and there has been a recent comprehensive metaanalysis [22] . This analysis included 50 separate published patient groups, but was limited because the underlying liver diseases were heterogeneous (22% were not for HCV), only 15 were published as a full paper, there was no individual patient data and most studies comprised clinic rather than population cohorts, which would increase the proportion of patients with increased liver enzymes. Also, not all studies reported whether patients with clinically obvious cirrhosis were included. Diagnostic accuracy of TE was expressed as the AUROC for hepatic fibrosis. These curves express the balance of sensitivity and specificity for a diagnostic test. An AUROC>0.8 is good, >0.9 is excellent and =1.0 is a perfect test. For the diagnosis of significant fibrosis (F2-F4), advanced fibrosis (F3-F4) and cirrhosis (F4) the AUROC were 0.84, 0.89 and 0.94, respectively. These are at least as good as other wellestablished non-biopsy markers. The statistical analysis determined that the optimum cutoff for the diagnosis of significant fibrosis and cirrhosis was 7.65 kPa and 13.01 kPa, respectively. Smaller systematic reviews of the diagnostic accuracy of TE confirmed the excellent diagnostic accuracy of TE, in particular for the identification of cirrhosis [23, 24] . The TE score cutoffs are calculated based on individual studies and are influenced by study heterogeneity. Some studies propose a number of different cutoffs depending on the question being asked. For example, one study looked at TE in diagnosing cirrhosis and reported wide ranging cutoffs of 6.0, 10.3, 16.9 and 14.3 kPa for 95% sensitivity, 95% specificity, best sum of sensitivity and specificity, and best diagnostic accuracy, respectively [25] . Likewise, the cutoffs established for one liver condition cannot be applied to another condition, as the pattern of liver injury and fibrosis will differ. Interpretation of Fibroscan results using cutoffs must be considered with this in mind. A useful recent review tabulates the operating characteristics of TE for the diagnosis of significant fibrosis and cirrhosis reported in a number of individual series [26] . For the diagnosis of significant fibrosis, in one cohort, a cutoff of 4 kPa gave a 94% sensitivity but 33% specificity, whereas in another, using a cutoff of 8.5 kPa the sensitivity was 90% but the specificity improved to 81% [26] . The studies were all relatively small and cutoffs were determined by meta-analysis with the limitations mentioned above. The analysis by Castera et al. [26] also demonstrates that the operating characteristics for the diagnosis of significant fibrosis (≥F2) are not as good as those for the diagnosis of cirrhosis. This can be expected from the fact that a pathologist must report F2 when there is any extension of fibrosis outside the portal tract, even a little bit; thus, overlap of TE scores with F1 is not surprising.
Unlike liver biopsy, with TE has excellent inter observer and intraobserver agreement. In 800 TE examinations in 200 patients by 2 examiners, the intraclass correlation coefficient was 0.98 [21] .
Although most of the studies of TE have been in groups of HCV-infected patients, studies have also been performed in other conditions, such as chronic hepatitis B. In 161 Chinese patients with chronic hepatitis B, Chan et al. [27] found the AUROC for the diagnosis of F3-F4 and F4 were excellent at 0.93 and 0.97, respectively. Another similar sized series of French chronic hepatitis B patients found comparable results with an AUROC for F4 of 0.9325. Interestingly, increased ALT slightly reduced the accuracy of TE but only significantly for those with mild fibrosis. Other studies have examined the accuracy of TE compared with liver biopsy in large patients groups with a variety of liver conditions and found similar degrees of accuracy [21, 28] .
In two studies of apparently healthy volunteers, mean TE score was 4.9 kPa (range 4.6-5. Either fatty liver increases TE, or, more likely, some of these individuals might have had liver fibrosis, as data so far suggest that TE scores are well correlated with the degree of fibrosis in non-alcoholic fatty liver disease [31] .
TE is one of many non-biopsy options available to the clinician in assessing liver fibrosis, and their comparison is important. A number of studies have compared TE to serum markers such as FT and APRI [32] [33] [34] [35] . Discordance in quantification of liver fibrosis between TE and FT was seen in 21-30% of examinations. In at least two studies, the cause of the discordance was attributed more often to FT than TE [32, 35] . This was especially true in the cases of cirrhosis, with TE giving a correct classification in 73% versus 25% by FT. Although simple to calculate, APRI appears to be less accurate for all levels of fibrosis than TE and FT. Studies have proposed algorithms that include both TE and FT to improve the accuracy of either test alone. However the combination appears only useful in diagnosing lower grades of fibrosis because the AUROC for TE plus FT is no better than TE alone for the diagnosis of cirrhosis [32] . Combining Fibroscan with markers such as FT or APRI [32] thus can improve the diagnostic accuracy of Fibroscan, although at the price of increased numbers of liver biopsies required to resolve discordance. Algorithms with the combination of TE and FT also add complexity to the testing process and are dependent on appropriate cutoff values being used for the population being studied.
Liver elastography has also been assessed using magnetic resonance elastography (MRE). While inside a standard MRI magnet, a pneumatic device sitting over the patient's liver emits shear waves. Special protocols are used to acquire a 'map' of elastography of entire liver cross sections. The early results are promising, with AUROC for the diagnosis of F≥1, F≥2, F≥3 and F=4 of 0.96-0.99, 0.92-0.99, 0.92-0.99 and 0.92-0.99, respectively [34, 35] . These values were significantly higher than TE and APRI [36] . MRE also appeared to be applicable to a wider patient group, including individuals who are obese and those with ascites, and gives information about a larger amount of liver than TE. However, these initial reports are in relatively small numbers (<100 patients) and although the AUROCs are impressive, the staging cutoff values varied significantly between the studies and misclassification of fibrosis still occurred in up to 25% of cases [37] . Also, when compared with TE, MRE is more expensive, more uncomfortable for the patient and less accurate in those with hepatic iron overload. Further studies are needed in this technique, which at the moment is of experimental use only.
Transient elastography: limitations
The limitations of TE are intuitive. Those patients with increased tissue between the probe and liver will variably attenuate the shear wave and the ultrasound waves. Thus, people with increased subcutaneous fat (in particular BMI>28), ascites or narrow intercostal spaces are more likely to be unsuitable for TE. Quoted failure rates are between 2.4% and 9.4% [38, 39] ; however, specific probes are available or in development for these situations. Recently, in a large community series, liver stiffness measurement could not be interpreted in 18% of cases predominantly as a result of results falling outside the manufacturers recommendations for interquartile range and success rate for readings [39] . Operator experience was found to be an important factor in improving interpretability rates.
Factors other than fibrosis, such as inflammation, could alter liver stiffness. During major ALT flares, the liver stiffness value is increased, but returns, to baseline once the ALT normalizes [21, 40, 41] . Those with stable aminotransferases were accurately assessed by TE, even if increased [28] . In patients with HCV infection in whom large fluctuations in ALT are unusual, TE values are not greatly influenced by ALT [42] . There is some effect of necroinflammatory activity (but not steatosis) on the TE scores in HCV, irrespective of aminotransferase levels [42] . Despite this, TE performs very well in HCV infection, despite the effect of inflammation, especially in the identification of advanced fibrosis. In that study, when TE was >10.8 kPa, the diagnosis of Metavir score ≥3 could be made with sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of 91%, 94%, 89% and 95%, respectively [42] . Also, if the TE score was <6 kPa, F2 or greater fibrosis (that is, any fibrosis extending out of the portal tract) could be ruled out with confidence (likelihood ratio 0.025).
The effect of inflammation is more relevant in hepatitis B, which can be characterized by dramatic necro inflammatory and ALT fluctuations. Studies attempting to determine optimal TE score cutoffs for the diagnosis of cirrhosis in chronic hepatitis B are few, and the suggested cutoffs vary [28, 43, 44] . This could be explained by a number of factors, including the lack of control for ALT variations prevalent in this disease. In one interesting study, Chan et al. [27] attempted to find optimal cutoffs for normal and increased ALT groups. Increased ALT was associated with a higher TE score (odds ratio 2.8, P<0.001) with the median score for bridging fibrosis being 10.7 kPa (range 5.2-34.3) for those with a normal ALT compared with 12.6 kPa (range 5.2-34.3) with an increased ALT. The difference for cirrhotic patients was even greater (12.3 versus 16.6 kPa). Thus, TE scores must be interpreted in the context of the level and trend of the ALT in chronic hepatitis B. Despite the more intensive inflammation in HBV infection, the suggested cutoffs are generally lower than those used to detect similar fibrosis stage in HCV patients. For example, a cutoff of 11 kPa to detect F4 is reported with sensitivity 93%, and NPV 99% [44] .
Evidence for the effect of hepatic steatosis and increased BMI on the elastography score is conflicting [20, 42] . Reassuringly, for the detection of cirrhosis, histological steatosis and obesity did not influence the performance of TE [45] .
The pattern of cirrhosis might also be relevant. Micronodular cirrhosis has a higher amount of fibrous tissue than macronodular cirrhosis, which might lead to falsely low TE scores in those with the latter [44] . Thus, TE might be less accurate in those with conditions prone to developing macronodules, which is more common in HBV infection.
If TE replaces liver biopsy, additional diagnoses such as fatty liver disease could be missed. However, TE is not designed as a complete replacement for liver biopsy, but a surrogate only for the quantification of liver fibrosis. In biopsies for chronic viral hepatitis, it is uncommon for an additional diagnosis that materially alters patient management to be identified [46] .
Studies of most non-invasive markers, including TE, usually demonstrate greater accuracy for advanced fibrosis compared with early fibrosis. In these early stages, fibrosis begins to expand within, and then extend outside, the portal tracts with only minor changes in collagen quantity. Such subtle changes in the pattern of fibrosis have minimal effect on liver elasticity, and limit the utility of TE in differentiating between lowers stages of fibrosis. Thus, algorithms proposing TE to distinguish between minor stages of fibrosis are more susceptible to error. Nevertheless, in a cohort of HBV patients, when the TE score was 5 kPa or less, the patient is likely to have F0 fibrosis with a PPV of 96%, and sensitivity of 92% [27] .
Proposed use of transient elastography in viral hepatitis
The operating characteristics of TE in the setting of chronic viral hepatitis are sufficient to allow its place in the algorithms for management. Liver biopsy limitations have been discussed at length, but the most pressing difficulty with biopsy is probably increasing patient reluctance to have one. It is not expected that TE can replace biopsy in all settings. If the operating characteristics of TE are taken into consideration, specific questions can be answered with accuracy so that our reliance on biopsy is reduced. We have outlined two algorithms, one for HCV and one for HBV, which can be used to guide management decisions. Thresholds for treatment will always be influenced by patient and clinical preference, but it would seem that in the absence of biopsy, TE will facilitate by allowing the decision to be tailored more closely to the patient's liver disease.
Chronic hepatitis C
For HCV infection, attitudes to treatment are dynamic, and take into consideration the efficacy and safety of current therapies, tailored to genotype. Some clinicians prefer to offer therapy to those with significant fibrosis, although some are willing to treat the infection, independent of whether significant liver injury has yet occurred. However, it is always relevant to know whether the patient has cirrhosis or not. Once a decision has been made to treat, those with advanced fibrosis genotype 2 or 3 benefit from an extended duration of therapy [47] . Those with cirrhosis have a lower chance of SVR and higher risk of treatment toxicity, and can be counselled appropriately [48] [49] [50] . Those with HCV cirrhosis are at risk of liver cancer and varices and should participate in surveillance programmes, even if they achieve SVR with therapy, but especially if they do not.
How can TE help here? We suggest that all patients considering treatment for HCV, could have a TE performed (Figure 2) . The result might encourage the ambivalent patient to have therapy, or steer the borderline patient away from it. Those with wellcompensated cirrhosis benefit from extended treatment duration for genotypes 2 and 3 (and possibly 1 in the context of trials). The optimal cutoff for this diagnosis is 13 kPa, maximizing sensitivity and specificity on the basis of the largest meta-analysis [22] . Those with TE scores >13 kPa need ongoing surveillance for HCC and oesophageal varices, as well as indefinite management by the liver clinic. Those with TE scores <13 kPa (without cirrhosis) who achieve SVR after therapy can be safely discharged from the clinic. A liver biopsy could be used for clarification when the TE score falls close to this cutoff. Finally, using a cutoff of 7.65 kPa, which was found to be the most accurate to diagnose F>1 in the large meta-analysis, an option for genotype 1 patients with scores <7.65 kPa could be anticipated as newer therapies are developed. In most cases, a liver biopsy is unlikely to contribute greatly in the decision algorithm for HCV treatment, unless other diagnoses are suspected. Using this algorithm, there is a risk that some patients with genotype 1 and low Fibroscan score will actually have some fibrosis. Some of these patients could be identified using FT, although using both tests in all patients adds complexity, benefiting only a small number [32] . Dynamic monitoring of elastography could be an alternate, although to date unproved, way to identify those patients with progressive liver disease not appreciated on the baseline examination.
The role of TE beyond the time of initial assessment is a growing field of research interest. TE scores have been shown to fall in all chronic hepatitis C patients on treatment; however, the fall was greater in those with SVR and especially in those with a rapid virological response [51] . Additionally, TE has been shown to be related to the development of HCC. In one series, a TE score of >10 kPa conferred a hazard ratio of 16.7 of developing HCC, whereas a cutoff of >25 kPa was associated with an hazard ratio of 45.5 [52] . In terms of predicting the presence of oesophageal varices, the results are mixed. A recent series produced AUROC for the diagnosis for any, and large, oesophageal varices of 0.84 and 0.87, values which are reasonably accurate but not sufficient to replace endoscopic surveillance of such a potentially serious complication [53] . However, TE is possibly more useful in predicting portal hypertension, with an AUROC of 0.95 for the detection of hepatic venous pressure gradient of >10 mm [54] .
Chronic hepatitis B
For HBV infection, management guidelines are continuously evolving, taking into consideration our greater understanding of natural history and therapeutic efficacy and safety. Most guidelines suggest patients be 'considered for treatment when HBV DNA levels are >2,000 IU/ml and/or the serum ALT levels are above the upper limit of normal for the laboratory, and liver biopsy shows moderate to severe active necroinflammation and/or fibrosis using a standardized scoring system (for example, at least grade A2 or stage F2 by Metavir scoring)' [55] . This reflects the current practice of many clinicians who will suggest a biopsy when the HBV DNA and ALT are increased, although there is some debate on the ALT threshold to use.
The current EASL guidelines state that HBV validated non-invasive makers could be used as an alternative to liver biopsy [55] . Is Fibroscan sufficiently well validated to be used in place of biopsy for HBV infection? The data are certainly less abundant than that available for HCV infection and data from the two main published cohorts is summarized in Table 2 . The elastography of the liver is affected by the more marked necroinflammation characterized by certain phases of HBV infection. To address this, Chan et al. [27] attempted to define optimal cutoffs for TE in chronic hepatitis B according to whether the ALT was increased or not. Using this approach, the accuracy of TE in HBV infection for the diagnosis of minimal or severe fibrosis is improved. For patients with an increased ALT, a TE score of <5 kPa had 92% sensitivity to exclude any fibrosis, <7.5 kPa had 96% sensitivity to exclude bridging fibrosis, >12 kPa had 98% specificity to diagnose bridging fibrosis and >13.4 kPa had 93% specificity to diagnose cirrhosis. For patients with a normal ALT, a TE score of <5 kPa had a 91% sensitivity to exclude any fibrosis, <6.0 kPa had a 93% sensitivity to exclude bridging fibrosis, >9.0 kPa had a 100% specificity to diagnose bridging fibrosis and >12 kPa had a 95% specificity to diagnose cirrhosis. Based on these operating characteristics, algorithms for the management of chronic hepatitis B were proposed in the same paper (Figures 3 and 4) . By utilizing the accuracy of Fibroscan at the extremes, and biopsying those with elastography results in the 'grey zone', in the Chan et al. [27] cohort, the need for biopsy was reduced by 58%. In addition to the management of patients under usual consideration for therapy (that is, increased ALT), up to one-third of patients with increased HBV DNA and laboratory normal ALT will have significant fibrosis (F≥2) or inflammation (A≥2) on biopsy [56] [57] [58] . At least half of the patients with chronic HBV infection have 'normal' ALT [50] . HBeAg-negative patients particularly have lower ALT, but a high rate of significant liver damage [59] . To avoid missing significant fibrosis, it has been suggested in recent guidelines that biopsy should be considered in all patients with viral replication, high normal or increased ALT and age >40 years [60] . Many patients are reluctant to accept this broad indication for biopsy, and if the biopsy shows mild disease, the interval for repeat biopsy has not been clearly defined. In this group of patients with normal ALT, TE could play a useful role given the published accuracy demonstrated to date.
There is also the issue of low viral load patients. Current international guidelines suggest antiviral treatment is only indicated if the HBV DNA is >2,000 IU/ ml (>105 copies/ml) [55, 60, 61] . However, moderate to severe inflammation and/or fibrosis has been shown to occur in up to 62% (persistent increased ALT) and 34% (transiently normal ALT) of a group with HBV DNA<2,000 IU/ml [62] . These patients would be denied treatment by these current guidelines despite active liver destruction, yet suggesting liver biopsy to all patients with low viral load might be overly burdensome. TE has the capacity to non-invasively screen these patients and identify those with significant liver injury. Fibroscan is quick, easy and accurate and, thus, is applicable to large lower risk groups. This strategy is likely to have greater population penetration and reduced cost and risk compared with biopsy. However, further data to validate the approach in this cohort is required.
Conclusions
Liver biopsy is the current gold standard in assessing the severity of liver damage in chronic viral hepatitis, yet it is far from the ideal tool. Liver TE is exciting new technology to aid the clinician who faces the many complicated decisions when treating viral hepatitis. It is impressively accurate, particularly at the extremes of liver damage, is well validated and within its recognized limitations, and has real utility in a busy outpatient viral hepatitis clinic. In chronic hepatitis C, it can identify those most likely to benefit from treatment, as well as those with cirrhosis who require more specific care. In chronic hepatitis B, it could screen groups previously excluded from treatment (normal ALT and low DNA) to identify the subgroup that would benefit from therapy. It cannot replace biopsy in all settings but it will narrow the group who do require biopsy and provide information on liver damage in patients for whom biopsy would probably not have been considered.
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